RxDoctor Payments Data

Madison Carey, PA

Physician Assistant · Lititz, PANPI 1194207928

Payments from drug & device makers

$2,693in general payments, 2019–2025

Across 25 payments — averaging $107.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$959
  • Seagen Inc.$375
  • E.r. Squibb & Sons, L.L.C.$251
  • AstraZeneca$125
  • Pfizer$125
  • Incyte Corporation$125
  • plus $733 from 6 others

What the payments were for

  • Food & beverage$2,693100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,693 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,872
Medicare patients
286
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide57$741,754
IbrancePalbociclib47$725,325
RevlimidLenalidomide30$575,717
ImbruvicaIbrutinib31$504,888
PomalystPomalidomide19$397,353
VenclextaVenetoclax21$254,047
CalquenceAcalabrutinib Maleate14$206,462
BrukinsaZanubrutinib16$191,390
Imatinib Mesylate27$78,343
EliquisApixaban59$39,020
Anastrozole75$1,407
Acyclovir73$1,204
Tamoxifen Citrate29$820
Hydroxyurea41$582
Dexamethasone17$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$125$764,344106 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$251$397,35319 claims
AstraZenecaCalquence$125$206,46214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Lititz

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →